\
&
Contact us
\
&
Contact us
Published on | 10 months ago
Programmes Culture and society Missions New European BauhausThe amended version of the Mission Work Programme has been published on the Funding and Tenders Portal. As part of the amendment, the Mission Work Programme includes the addition of a new destination for the New European Bauhaus. The European Union wants to put the New European Bauhaus (NEB) on a stable footing going forward as a self-standing Facility anchored in the Horizon Europe Strategic Plan 2025-2027. This New European Bauhaus destination will therefore pave the way for the New European Bauhaus Facility to be set in place from 2025 onwards.
The New European Bauhaus destination includes 3 call topics:
The call topics will open on 7 May 2024 and will close on 19 September 2024.
To receive updates and news items on the New European Bauhaus don’t forget to select "Bauhaus" as topic in your NCP Flanders website profile.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
